The University of Florida Department of Urology invites you to attend
Castration Resistant Prostate Cancer
Presenter: Scott B. Sellinger, MD
President, Tallahassee Division – Advanced Urology Institute
Wednesday, April 10, 2019 7:00 – 7:45 AM
Urology Conference Room M-203C
Upon completion of this activity, participants should be able to:
Define non-metastatic and metastatic castrate resistant prostate cancer
Understand the role of androgen signaling and androgen receptor activity in the management of advanced prostate cancer
Understand the efficacy and side effect profiles of several novel therapies for both non-metastatic and metastatic castrate resistant prostate cancer
Emphasize the role of the urologist from early diagnosis of prostate cancer to advanced disease
Urologists, Residents, Nurses, Physician Assistants, and Staff
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Department of Urology within the University of Florida’s College of Medicine is hosting this free event which is internally supported.
If you have any questions please feel free to contact Stephanie Stenner at Stephanie.firstname.lastname@example.org.
Dr. Sellinger has disclosed that he is a consultant for Astellas, Pfizer and Jannsen and a speaker for Astellas, Pfizer, Janssen and Dendreon. Dr. Vincent Bird, Planning Committee, is a consultant for Boston Scientific. No one else in a position to control content has any financial relationship to disclose.
Section Number: 9071